Abstract Objective To study the changes in pulmonary function and fractional exhaled nitric oxide in exhaled breath (FeNO) in asthmatic children who have different responses to regular treatment. Methods A total of 52 asthmatic children who had a good compliance with regular stepped control treatment were selected as subjects. They were followed up every three months to evaluate the asthma control level, pulmonary ventilation function, and FeNO for 9 months. Besides, medications for asthma control were recorded. Results At three follow-up points (months 3, 6, and 9), the percentage of asthmatic children who used the first or the second level of control treatment in the stable group (with stable response to the treatment) was significantly higher than in the unstable group (with unstable response to the treatment) (P<0.05), while the percentage of asthmatic children who used the third level of control treatment in the stable group was significantly lower than in the unstable group (P<0.05). At the three follow-up points, the stable group had a significantly higher ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) than the unstable group (P<0.05); at the 3-month and 9-month follow-up points, the stable group had a significantly higher percentage of predicted maximum mid-expiratory flow (MMEF%) than the unstable group (P<0.05); at the initial evaluation and 3-month follow-up point, the stable group had a significantly higher FeNO than the unstable group (P<0.05). Conclusions Continuously monitoring FEV1/FVC, MMEF% and FeNO is useful in the early evaluation of the responses to treatment in children with asthma.
Risma K, Jordan MB. Hemophagocytic lymphohistiocytosis: updates and evolving concepts[J]. Curr Opin Pediatr, 2012, 24(1): 9-15.
[21]
Kercsmar C. Exhaled nitric oxide in the diagnosis and management of childhood asthma[J]. Ther Adv Respir Dis, 2010, 4(2): 71-82.
[22]
Prado CM, Yano L, Rocha G, et al. Effects of inducible nitric oxide synthase inhibition in bronchial vascular remodelinginduced by chronic allergic pulmonary inflammation [J]. Exp Lung Res, 2011, 37(5): 259-268.
[2]
Janka GE. Fami l ial and acquired hemophagocytic lymphohistiocytosis[J]. Annu Rev Med, 2012, 63: 233-246.
[23]
Franklin PJ, Stick SM. The value of FeNO measurement in asthma management the motion against FeNO to help manage childhood asthma-reality bites[J]. Paediatr Respir Rev, 2008, 9(2): 122-126.
[3]
Gholam C, Grigoriadou S, Gilmour KC, et al. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management[J]. Clin Exp Immunol, 2011, 163(3): 271-283.
[24]
Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guidelinebased treatment for inner-city adolescents and young adults: a randomised controlled trial[J]. Lancet, 2008, 372(9643): 1065-1072.
[4]
Ta n g YM, Xu XJ. Advances in hemophagocytic lymphohistiocytosis: pathogenesis, early diagnosis/differential diagnosis, and treatment[J]. Scientific World Journal, 2011, 11(1): 697-708.
[5]
Voskoboinik I, Thia MC, Trapani JA. A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis[J]. Blood, 2005, 105(12): 4700-4706.
[6]
Sanchez IP, Leal-Esteban LC, Alvarez-Alvarez JA, et al. Analyses of the PRF1 gene in individuals with hemophagocytic lymphohystiocytosis reveal the common haplotype R54C/A91V in Colombian unrelated families associated with late onset disease[J]. J Clin Immunol, 2012, 32(4): 670-680.
[7]
Martinez-Pomar N, Lanio N, Romo N, et al. Functional impact of A91V mutation of the PRF1 perforin gene[J]. Hum Immunol, 2013, 74(1): 14-17.
[8]
Trambas C, Gallo F, Pende D, et al. A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin[J]. Blood, 2005, 106(3): 932-937.
[25]
Fritsch M, Uxa S, Horak F Jr, et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6-months study[J]. Pediatr Pulmonol, 2006, 41(9): 855-862.
[26]
Spanier AJ, Hornung RW, Kahn RS, et al. Seasonal variation and environmental predictors of exhaled nitric oxide in children with asthma [J]. Pediatr Pulmonol, 2008, 43(6): 576-583.
[9]
H e n t e r J I, H o r n e A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2): 124-131.
[10]
Zur Stadt U, Beutel K, Kolberg S, et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A[J]. Hum Mutat, 2006, 27(1): 62-68.
[11]
Lichtenheld MG, Olsen KJ, Lu P, et al. Structure and function of human perforin[J]. Nature, 1988, 335(6189): 448-451.
[12]
An O, Gursoy A, Gurgey A, et al. Structural and functional analysis of perforin mutations in association with clinical data of familial hemophagocytic lymphohistiocytosis type 2 (FHL2) patients[J]. Protein Sci, 2013, 22(6): 823-839.
[27]
Busse WW, Pedersen S, Pauwels RA, et al. START Investigators Group. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma[J]. J Allergy Clin Immunol, 2008,121(5): 1167-1174.
[13]
Kägi D, Odermatt B, Seiler P, et al. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice[J]. J Exp Med, 1997, 186(7): 989-997.
